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A B S T R A C T
The mortality rate associated with HIV infection plummeted after the introduction of effective
antiretroviral therapy pioneered two decades ago. As a result, HIV-infected people now have life
expectancies comparable to that of HIV-uninfected individuals. Despite this, increased rates of
osteoporosis, chronic liver disease, and in particular cardiovascular disease have been reported among
people living with HIV infection. With the aging HIV-infected population, the burden of these comorbid
illnesses may continue to accrue over time. In this paper, we present an overview of the aging HIV-
infected population, its epidemiology and the many challenges faced. How to deﬁne and measure
successful aging will also be reviewed. Finally, opportunities that may help mitigate the challenges
identiﬁed and ensure successful aging among people living with HIV infection will be examined.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Introduction
The introduction of potent antiretroviral therapy (ART) has
signiﬁcantly improved survival among people living with HIV
infection (PLWH), with life expectancy now close to that of the
HIV-negative population (Lohse et al., 2007). Globally, the
proportion of PLWH receiving ART increased in the 5 years from
2010 to 2015, leading to signiﬁcant reductions in AIDS-related
deaths and increased life-expectancy (Centers for Disease Control
and Prevention, 2016). The Centers for Disease Control and
Prevention (CDC) estimated that by 2017, more than half of PLWH
in the USA would be older than 50 years (Justice, 2010). Successful
aging may be more difﬁcult among PLWH because of their
increased vulnerability to the development of multiple comorbid-
ities over time compared to the general population (Guaraldi et al.,
2011).
Epidemiology of the aging population
In the USA, the proportion of PLWH aged at least 50 years
increased by over 100% from 2001 to 2014 (Centers for Disease
Control and Prevention, 2009; Centers for Disease Control and
Prevention, 2015). Currently, persons aged over 50 years comprise
42% of all PLWH (Centers for Disease Control and Prevention,
2009). Some regions of the country already have the majority of
their HIV-positive patients over 50 years (San Francisco Depart-
ment of Public Healh., 2013). By the end of 2014, 58% of PLWH in
San Francisco were over 50 years of age.
HIV-infected persons over the age of 50 years in the USA
comprise two groups: the majority are persons infected with HIV
at a younger age who are aging due to the success of ART; the
others comprise persons who are newly infected or newly
diagnosed with HIV, who make up 17% of all persons with a
new diagnosis of HIV (Centers for Disease Control and Prevention,
2016).
The proportion of PLWH over 50 years of age is also increasing
in other parts of the world. The prevalence rate of older PLWH has
increased consistently in all regions at varying rates since 2007,
with Western/Central Europe and North America having the
highest proportions of PLWH over 50 years (30%) and the lowest
rates in regions of Sub-Saharan Africa (7.6%) (Centers for Disease
Control and Prevention, 2016; United Nations AIDS Report, 2013).
Challenges faced by the aging population
As a result of the demographic changes discussed above,
caring for PLWH now comes with the additional complexity of
managing diseases commonly associated with aging. Increased
rates of osteoporosis, frailty, diabetes, malignancy, chronic liver
disease, chronic kidney disease, and in particular, cardiovascular
diseases have been reported in PLWH when compared to the
general population (Palella et al., 2006; Guerri-Fernandez et al.,
2013; Clifford, 2017; Janssen et al., 1992). Data from the Veterans
Aging Cohort Study (VACS) compared the rates of comorbidities
experienced by over 30 000 HIV-positive veterans to those of
their HIV-negative counterparts and demonstrated increased
rates of individual age-related comorbidities, as well as multi-
morbidity, in the HIV-positive group. However, it should be
noted that HIV-positive and negative populations were not
completely matched; for example, the HIV-positive group had
higher rates of drug dependency and lower socioeconomic
status (Goulet et al., 2007). This study raises two important
questions. Firstly, are PLWH aging in an accelerated or
accentuated fashion as a result of increased comorbidities
(Pathai et al., 2014)? Secondly, are these comorbidities
attributable to the HIV infection itself or to the increased rates
of traditional risk factors associated with lower socioeconomic
status and increased rates of substance abuse seen in PLWH, as
suggested by the VACS cohort, or to ART toxicities?
Cardiovascular disease
Cardiovascular disease (CVD) is a leading cause of death in
PLWH on effective ART (Rodger et al., 2013). Although the overall
mortality in those living with HIV in the USA halved between
1999 and 2013, deaths from CVD increased two-fold despite a
decrease in CVD-related mortality in the general population
(Feinstein et al., 2016). Multiple factors have been attributed to
the increased CVD risk observed in PLWH, including the HIV
infection itself, ART toxicity, and increased rates of traditional risk
factors including smoking, diabetes mellitus, hypertension, and
dyslipidemia (Triant et al., 2007; Saves et al., 2003). Although of
unclear mechanism, individuals who reported recent use of
abacavir were shown to have a 90% greater risk of acute
myocardial infarction compared to those who had not used
abacavir (Sabin et al., 2008). Even after correcting for channeling
bias (i.e., patients who have higher CVD risk are preferentially
prescribed abacavir), a follow-up study still demonstrated an
excess risk of CVD with abacavir use (Sabin et al., 2016). At
present, this association remains debatable, as several other large
studies have not shown an association between abacavir and CVD
(Brothers et al., 2009; Ribaudo et al., 2011).
Higher myocardial infarction rates were consistently observed
across three age categories of HIV-positive veterans in the VACS
cohort compared to HIV-negative controls. This persisted after
adjustment for Framingham risk factors, substance abuse, and
geographic location, which would at least in part take socioeco-
nomic factors into account. There was an increased risk of incident
acute myocardial infarction of 48% (hazard ratio (HR) 1.48, 95%
conﬁdence interval (CI) 1.27–1.72) amongst HIV-positive veterans
(Armah et al., 2014). In the absence of major CVD risk factors, HIV-
positive veterans had a two-fold increased risk of myocardial
infarction compared to HIV-negative veterans (HR 2.0, 95% CI 1.0–
3.9; p = 0.044), suggesting that at least for myocardial infarction,
the increased rates seen in PLWH are not entirely explained by an
over-representation of traditional CVD risk factors (Paisible et al.,
2015).
A more recent study from the VACS cohort also demonstrated
an association between HIV infection and heart failure with
preserved and reduced ejection fractions. Although socioeco-
nomic status was not accounted for in the overall analysis, the
association between heart failure and HIV persisted after
adjustment for multiple traditional risk factors and remained
unchanged even after restricting the analysis to participants
without hypertension, substance use, or smoking history
(Freiberg et al., 2017).
Osteoporosis and fracture
PLWH are six times more likely to have low bone mineral
density and almost four times more likely to have osteoporosis
compared to the general population (Brown and Qaqish, 2006). In
a large cohort study, HIV infection was shown to be indepen-
dently associated with low bone mineral density, an association
that remained despite adjustment for traditional risk factors such
as age, sex, and smoking status, as well as educational level
(Cotter et al., 2014). Higher rates of hip fracture (four times higher
risk), non-hip fracture (63% increased risk), and all clinical
fractures (75% higher risk) have also been demonstrated in PLWH,
although it should be noted that in the latter study, which
examined fractures in PLWH, data on drug use and socioeconomic
status were not included (Guerri-Fernandez et al., 2013).
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Malignancy
Although the rates of AIDS-deﬁning malignancy (Kaposi sarcoma,
cervical cancer, and non-Hodgkin lymphoma) have declined over
time with ART, the rates of non-AIDS-deﬁning cancer continue to
increase (Bedimo et al., 2009; Shiels et al., 2009). In particular,
infection-related cancers (i.e., anal cancer, Hodgkin lymphoma, and
liver cancer) and cancers highly associated with smoking (i.e., lung
and laryngeal cancer) have higher incidence rates in HIV-infected
individuals than inthe general population(Shiels et al., 2009). Rather
than attributing the latter to the direct effect of HIV, it is more likely
that the increased rates of smoking in PLWH may be responsible.
Tobacco smoking rates amongst PLWH reportedly range from 40% to
70%, equating to two to three times higher than the general
population (Petoumenos et al., 2011). A number of studies have
demonstrated increased rates of lung cancer after adjustment for
smoking status in PLWH, although these have been limited by a lack
of dataon cumulative smokingexposure (Engelsetal., 2006; Kirkand
Vlahov, 2007). The underlying mechanism for increased rates of
infection-related malignancies in PLWH is also not entirely clear, but
may be related to either increased exposure to oncogenic viruses or
persistent infection related to HIV-induced immune suppression
(Shiels et al., 2009).
Chronic liver disease and kidney disease
Arising from shared modes of acquisition, the prevalence of co-
infection with hepatitis B and C viruses amongst PLWH is
approximately 25 times higher than in the general population
(8% versus 0.3% for hepatitis B virus (HBV), and 30% versus 1.3% for
hepatitis C virus (HCV)) (Kellerman et al., 2003; Staples et al., 1999;
Denniston et al., 2014). Co-infection with HIV accelerates the
progression of liver ﬁbrosis among HBV- and HCV-infected
patients, leading to higher rates of cirrhosis and hepatocellular
carcinoma (Castellares et al., 2008; Silverberg et al., 2015).
HIV-associated nephropathy (HIVAN) used to be the most
common cause of end-stage renal disease (ESRD) requiring
hemodialysis among HIV-infected persons (Winston et al.,
1998). In the era of ART, the incidence of HIVAN has declined,
but the overall rates of chronic kidney disease (CKD) have
remained stable (Eggers and Kimmel, 2004). The prevalence of a
glomerular ﬁltration rate <60 ml/min among HIV-infected persons
ranges from 5% to 10% (Campos et al., 2016). HIV-infected persons
are particularly at risk of developing CKD because of several risk
factors, including exposure to speciﬁc antiretrovirals such as
tenofovir disoproxil fumarate, as well as increased rates of other
comorbidities including hypertension and diabetes.
HIV neurocognitive disease
The prevalence of HIV-associated dementia was estimated at 10–
15% before the era of ART. The prevalence dropped dramatically after
the introduction of ART to approximately 2% (Heaton et al., 2010).
Despite this, some studies have shown that even at younger ages and
with well-controlled HIV infection, more than half of PLWH have
varying degrees of neurocognitive dysfunction (Clifford, 2017;
Heaton et al., 2010). It is important to note that this ﬁnding is driven
primarily by asymptomatic and mild neurocognitive dysfunction,
the relevance of which is unclear. Additionally, neurocognitive
testing may be signiﬁcantly impacted by socioeconomic status, test
bias, and contextual factors (Arentoft et al., 2015).
Frailty and other aging-related conditions
Deﬁned as an aging-related syndrome that predisposes an
individual to an increased risk of multi-morbidity and mortality,
frailty is estimated to occur in 5–19% of PLWH. Data from a study
that examined frailty in HIV-positive and negative intravenous
drug users (IVDU) demonstrated that although frailty was strongly
associated with advanced HIV, the prevalence of frailty in IVDU
with well-controlled HIV was similar to that in HIV-negative IVDU,
suggesting that untreated HIV infection contributes to the
development of frailty (Piggott et al., 2013).
Other geriatric conditions have also been reported at increased
rates in PLWH. Data from a cohort of 155 HIV-infected patients
aged at least 50 years and receiving ART for at least 3 years,
demonstrated that more than half of participants had at least two
geriatric syndromes. The most common were pre-frailty (56%),
difﬁculty with activities of daily living (46%), cognitive impairment
(46%), depression (40%), visual impairment (35%), falls (26%), and
urinary incontinence (25%). Although there was no HIV-negative
control group in the study, when compared to other studies in the
literature, these prevalence rates were equivalent to cohorts in the
general population who were 65 years and older (Greene et al.,
2015). Of note, 23% of subjects in this cohort were current smokers,
and IVDU was the mode of HIV acquisition in 12% of the study
population, with 5% reporting ongoing use of intravenous drugs.
Seventy-four percent of subjects had exposure to older-generation
ART such as didanosine, zalcitabine, stavudine, and zidovudine,
although unexpectedly this was associated with decreased rates of
geriatric syndromes, potentially resulting from survival bias, but
overall making it difﬁcult to apply the ﬁndings to contemporary
cohorts.
Mechanisms behind the increased burden of chronic illnesses in HIV
infection
The observation that PLWH are experiencing more chronic
illnesses over time may simply be a reﬂection of the aging
population with the success of ART. Hence, this perceived higher
risk of developing these comorbid diseases among HIV-positive
individuals may represent a cohort effect. However, the occurrence
of these comorbid illnesses at younger ages and at frequencies
comparable to much older individuals in the general population, as
well as the over-representation of risk factors for these chronic
diseases among PLWH, argue for mechanisms beyond a cohort
effect.
It is clear that the increased rates of comorbid illness observed
in PLWH cannot be entirely attributed to HIV infection alone and
are likely to represent a complex interplay of factors, including
differing demographics and socioeconomic status, higher rates of
traditional risk factors, co-infections and opportunistic infections
and associated inﬂammation, and exposure to ART, along with the
direct effect of the HIV infection itself (Burch et al., 2016).
As previously discussed, traditional risk factors for developing
chronic diseases are found in excess in PLWH. For example,
increased rates of smoking, a strong risk factor for malignancy,
cardiovascular, bone, chronic kidney, and liver diseases, as well as
neurocognitive dysfunction and frailty, have repeatedly been
reported across a number of HIV acquisition risk groups (Niaura
et al., 2000).
Substance abuse, including alcohol and intravenous drug use, is
also highly prevalent in PLWH and has been linked to CVD, geriatric
syndromes, and increased all-cause mortality (Chander et al.,
2006). Co-infections with HBV and HCV, as mentioned previously,
lead to a higher burden of hepatocellular carcinoma, and HCV
infection is also an independent risk factor for osteopenia and
osteoporosis (Bedimo et al., 2016). Other traditional risk factors for
the development of chronic diseases, including hypertension,
diabetes, dyslipidemia, and obesity, are all seen at increased rates
in PLWH.
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Along with traditional risk factors, exposure to certain
antiretroviral agents has also been shown to contribute to the
development of some comorbid illnesses. For example, tenofovir
disoproxil fumarate is associated with osteoporosis and kidney
disease (Cooper et al., 2010). As discussed previously, abacavir has
been linked to acute myocardial infarction (Sabin et al., 2008), and
older-generation nucleoside reverse transcriptase inhibitors
(NRTI) such as zidovudine, stavudine, and didanosine, as well as
protease inhibitors, have been associated with anemia, dyslipide-
mia, and insulin resistance.
Untreated HIV has been associated with increased levels of
immune activation and inﬂammation, as well as endothelial
dysfunction, altered coagulation, platelet dysfunction, and gut
microbial translocation, all of which are factors known to
contribute to the development of chronic diseases such as CVD.
Likewise, co-infection with cytomegalovirus and HCV contributes
to immune activation. Elevated levels of systemic inﬂammatory
markers (e.g., soluble CD14, tumor necrosis factor (TNF)), which
represent a hallmark of HIV infection, have been shown to predict
not only mortality, but also the development of several of the
comorbid illnesses discussed previously. The maintenance of viral
suppression through the use of ART reduces but does not fully
normalize this level of inﬂammation (Hearps et al., 2012).
However, in patients on effective ART, the residual effect of HIV
infection itself on the development of comorbidities and on
mortality remains controversial, with further research required in
this area.
Successful aging
Successful aging in the general population
Although of critical importance to the general population, there
is no consistent deﬁnition of successful aging that has been
accepted by the research community. Successful aging, when
compared to usual aging, occurs when extrinsic factors such as
diet, exercise, and psychosocial factors play a neutral or positive
role instead of intensifying the effects of aging (Rowe and Kahn,
1987). To date, there are over 25 unique deﬁnitions of successful
aging, leading to a wide range of prevalence rates (1–94%, median
35%) (Depp et al., 2010). Current deﬁnitions stem from the classical
deﬁnition by Rowe and Kahn, which states that successful aging
comprises three major criteria: avoidance of disease and disease-
related disability (including risk factors for developing them), high
cognitive and physical functional capacity (i.e., sustaining physical,
mental, and emotional aptitude for performing activities), and
active engagement with life (i.e., maintaining productivity and
keeping valuable interpersonal relations) (Rowe and Kahn, 1997).
Of these criteria, physical and/functional disability is the one
included as a component of more than half of the deﬁnitions of
successful aging.
However, these deﬁnitions are not necessarily in keeping with
the opinions of older persons with regard to aging. In one study,
half of participants considered themselves successful agers based
on a self-rated scale, while only 18% met the successful aging
criteria of Rowe (Strawbridge et al., 2002). In another study, 92% of
older community-dwelling adults rated themselves as successfully
aging despite having chronic illnesses or physical disability
(Montross et al., 2006). In these studies, older adults emphasized
independence, resilience, coping mechanisms, and overall well-
being as the more important components of successful aging.
Successful aging in the HIV-infected population
HIV infection poses unique obstacles to achieving successful
aging. Apart from being predisposed to multi-morbidity and
polypharmacy, PLWH are more vulnerable to developing cognitive
and psychiatric impairments that contribute to a loss of personal
control, life satisfaction, and productivity (Vance et al., 2011).
Successful aging has not been studied well in the context of HIV
infection and thus predictors of successful aging among PLWH are
not known.
The deﬁnition of successful aging in HIV has been based on the
achievement of certain quality-of-life outcomes, which include
attaining a well-adapted affective state (i.e., absence of depression
and maintenance of high morale), ﬁnding meaning in life despite
chronic illness, and sustaining valued activities and relationships,
rather than on the attainment of physical health (Kahana and
Kahana, 2001). Data from one study that used a self-rated
successful aging scale employed in the general population, found
that two-thirds of HIV-positive participants had high scores on the
self-rated scale, although their scores remained lower than HIV-
negative participants matched by age, sex, race, and educational
attainment (Moore et al., 2013). They further demonstrated that
although HIV-positive participants had lower physical and mental
functioning and experienced greater psychosocial stressors
compared to their HIV-uninfected counterparts, HIV-positive
individuals had similar levels of optimism, personal mastery,
and social support. Thus, they concluded that even if PLWH had
physical impairment or disability, the achievement of successful
psychosocial aging was possible.
The HIV landscape is dominated by health disparity. HIV
disproportionately affects economically disadvantaged individuals
(i.e., those who are below the poverty threshold, disabled, and
unemployed), men who have sex with men (MSM), and blacks.
These vulnerable groups already carry an excessive burden of
morbidity and mortality even in the absence of HIV infection
(Stringhini et al., 2017; Emlet, 2016; Harper et al., 2007).
Furthermore, these population groups are not mutually exclusive,
which further impacts health outcomes. The health disparities also
widen with aging as more disabilities and chronic illnesses
accumulate. In the USA, the overwhelming majority of HIV-
infected individuals are male, of whom the majority are MSM. As a
group, MSM are vulnerable to social stigma, discrimination, social
isolation, and victimization, which persist throughout life and bear
lifelong negative physical, social, and psychological consequences;
these ultimately lead to poor health outcomes (Emlet, 2016). These
additional stressors pose a considerable challenge to successful
aging. Furthermore, substance abuse, which is also linked with
adverse health outcomes, is intricately tied not only to these social
stressors but also to low socioeconomic status and racial disparity.
Path to successful aging in the HIV-infected population (Figure
1)
Initiation of ART regardless of CD4+ T-cell count
CD4+ T-cell counts of <500 cells/ml have been linked to higher
mortality from both AIDS-deﬁning and non-AIDS deﬁning
malignancies, death from liver disease, and risk for incident
CVD, CKD, and fragility fractures (Collaboration of Observational
HIVEREiE et al., 2012; Lichtenstein et al., 2010; Yong et al., 2011;
Weber et al., 2006; Monforte et al., 2008; Ganesan et al., 2013).
Early initiation of ART at higher CD4+ T-cell counts is more likely to
result in patients achieving and maintaining CD4+ T-cell counts
>500 cells/ml. In a study of 655 patients who initiated ART, only
patients with a baseline CD4+ T-cell count >350 cells/ml
experienced a full immunological recovery after 6 years of viral
suppression (Moore and Keruly, 2007).
The beneﬁt of early initiation of ART also extends beyond CD4+
T-cell normalization. In the Strategic Timing of Antiretroviral
Treatment (START) study, a randomized controlled trial involving
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more than 4500 patients with CD4+ T-cell counts >500 cells/ml
who were randomized to initiate ART immediately or to have ART
deferred until their CD4+ T-cell count decreased to <350 cells/ml or
until the development of AIDS, it was found that immediate
initiation of ART not only led to fewer serious AIDS-related events
(HR 0.28; p < 0.001), but also resulted in fewer serious non-AIDS-
related events, including myocardial infarction, stroke, coronary
revascularization, ESRD, liver disease, non-AIDS-deﬁning cancer,
and death from these comorbidities (HR 0.61; p < 0.04) (Group ISS
et al., 2015). In both the immediate and deferred arms of the trial,
the mean CD4+ T-cell count remained >500 cells/ml at every time
point over 5 years. This led to a paradigm shift in the treatment of
HIV infection. At present, ART initiation is recommended for all
HIV-infected patients regardless of CD4+ cell count (Panel on
Antiretroviral Guidelines for Adults and Adolescents, 2016).
Use of safer ART
Although the net beneﬁt of viral suppression and immune
recovery with the use of ART among PLWH is an improvement in
the lipid proﬁle (i.e., lowering the total cholesterol to high density
lipoprotein ratio) (Riddler et al., 2003), older-generation protease
inhibitors (e.g., indinavir, lopinavir, fosamprenavir) and thymidine
NRTI (e.g., stavudine, didanosine, zidovudine) have been linked to
the development of dyslipidemia and insulin resistance by
inhibiting several important molecular pathways in lipid metabo-
lism and insulin signaling (Non et al., 2017a). Older protease
inhibitors have also been associated with an increased cardiovas-
cular risk because of their effects on lipid metabolism (Group DADS
et al., 2007). On the other hand, until recently it was thought that
newer protease inhibitors (e.g., atazanavir and darunavir) did not
confer these risks (Overton et al., 2012; Kamara et al., 2016; Noor
et al., 2006; Yan and Hruz, 2005; Aberg et al., 2012; Monforte et al.,
2013). However, recent data from the D:A:D cohort showed that
darunavir was independently associated with a 59% higher risk of
CVD per 5 years of exposure, while atazanavir was protective
(Ryom et al., 2017). However, these data need to be corroborated in
other large observational cohorts.
Integrase inhibitors are the newest class of antiretroviral
agents. Most experience has been with the use of raltegravir,
which has been on the market for 10 years now. It has not been
associated with dyslipidemia, insulin resistance, or lipodystrophy.
Likewise, it has not been linked to cardiovascular, bone, or kidney
disease. Current guidelines in the USA (Panel on Antiretroviral
Guidelines for Adults and Adolescents, 2016) and Europe
(European AIDS Clinical Society, 2016) reﬂect the important shift
to using safer antiretroviral medications. Because of their potency
and favorable long-term safety proﬁles, integrase inhibitor-based
therapy is now the recommended ﬁrst-line therapy for treatment-
naïve patients.
Newer treatment options are also being investigated that
promise to provide safer regimens for the treatment of HIV
infection, including new drug formulations and combination
therapies (Gallant et al., 2016; Mills et al., 2016; Sax et al., 2017;
Llibre et al., 2017; Joly et al., 2017; Cahn et al., 2016).
Application of primary prevention and screening guidelines and
aggressive control of risk factors
A recent study from the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD) on population
attributable fractions (PAFs; proportion of cases avoided if a risk
factor was not present, holding all other risk factors constant)
showed that 43%, 41%, and 38% of myocardial infarction could have
been avoided if HIV-positive individuals had not had elevated total
cholesterol, hypertension, or smoking, respectively (Althoff et al.,
Figure 1. Factors associated with successful aging in HIV.
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2017). It also showed that the PAFs for these three risk factors were
considerably higher compared to having uncontrolled viremia (6%)
and a lower CD4 count (10%). This study emphasizes the
importance of screening for and aggressively controlling tradi-
tional risk factors that contribute to CVD.
Smoking leads to almost all comorbidities seen with increasing
incidence in the aging HIV-infected population. The high PAF
associated with smoking is consistent in all studies (Althoff et al.,
2017). It is estimated that HIV-positive smokers lose 140% more
life-years compared to non-smokers (Helleberg et al., 2013). A
recent modeling study demonstrated that HIV-infected smokers
aged 40 years lose >6 years of life expectancy from smoking,
potentially a greater loss of life expectancy than that resulting from
the HIV infection itself (Reddy et al., 2016). Smoking likely
contributes to higher rates of inﬂammation among PLWH as well.
Compared to non-smokers, PLWH who smoke have higher levels of
inﬂammatory markers, including soluble CD14 and expression of
HLA-DR on both CD8+ and CD4+ T-cells (Cioe et al., 2015). Because
of the considerably high smoking rates among PLWH, smoking
cessation should be an integral part of routine HIV care.
Annual screening for diabetes and dyslipidemia, and frequent
blood work to monitor liver and kidney toxicity from prescribed
antiretroviral drugs are recommended for all HIV-positive patients.
In addition, it is recommended that co-infection with HCV and HBV
is also screened for at clinic entry and regularly thereafter,
depending on additional risk factors for acquiring viral hepatitis. It
is recommended that screening for osteoporosis is started at age 50
years for all PLWH, a cut-off that is much younger than that applied
in the general population, given the higher rates of osteoporosis
and fracture among PLWH. The recommendations for cancer
screening are not different from those for the general population.
However, aggressive screening for lung cancer for high-risk
patients should be emphasized given the high prevalence of
smoking among PLWH.
The most recent 2013 American College of Cardiology (ACC)/
American Heart Association (AHA) guidelines on the management
of cholesterol in the general population, expanded the indication
for statin use for the primary and secondary prevention of
atherosclerotic CVD (Stone et al., 2014). These new guidelines
introduce a new method for calculating cardiovascular risk called
the pooled cohort equation (PCE). Individuals with a PCE score of
7.5%, even in the absence of diabetes, dyslipidemia, or prior
history of a CVD, are recommended to use statins for the primary
prevention of CVD. Validation studies in the general population
have shown that the PCE overestimates the true risk of CVD by as
much as 150% (Ridker and Cook, 2013). In contrast, studies in the
HIV-positive population have shown that the PCE underestimates
cardiovascular risk among PLWH (Thompson-Paul et al., 2016;
Regan et al., 2015). Despite this discrepancy, the use of CVD risk
assessment tools is still strongly advocated, especially in the aging
HIV-infected population (Grinspoon et al., 2008).
Statins are underutilized among PLWH. In a cohort of HIV-
positive patients who were older than 40 years at the Washington
University Virology Clinic, two-thirds were not prescribed statins
despite a strong indication for their use based on the new ACC/AHA
guidelines (Non et al., 2017b). Prescriber-related factors may serve
as a major driver for the underutilization of statins. A survey was
conducted of all physicians who take care of HIV patients at
Washington University and it was found that most providers had
some awareness of the 2013 ACC/AHA guidelines, but few routinely
used the PCE calculator in their practice (Non et al., 2017c). The top
three barriers to prescribing statins identiﬁed were concerns for
drug–drug interaction, polypharmacy, and poor medication
adherence.
Addressing health disparity
As the population ages, the health disparities based on sexual
orientation, ethnicity, socioeconomic status, and disability widen.
Thus, successful aging is fundamentally allied to narrowing the gap
in health outcomes between different population groups. This
requires a concerted effort from the patient (i.e., personal
responsibility for his/her health), the physician (i.e., cultural
sensitivity, non-discrimination policy, delivery of excellent, cost-
effective, and evidence-based care), the healthcare system (i.e.,
improvements in access to medical care, provision of universal
insurance coverage), and the government (i.e., national leadership,
consistent and bipartisan efforts, promotion of medical and social
research). In addition, a targeted intervention to promote social
engagement among HIV-infected MSM is necessary to address
longstanding social stigma and social isolation. Social support and
social network size have been shown to be positively associated
with physical and mental health in older MSM (Fredriksen-
Goldsen et al., 2015). Together with health-promoting behaviors
(i.e., physical activity, avoidance of smoking, avoidance of alcohol/
substance use), social support contributes to resilience, i.e., the
ability to adapt well in the face of adverse circumstances (e.g.,
disability, chronic illnesses). In the general population, resilience
despite physical and cognitive impairments has been associated
with successful aging (Jeste et al., 2013).
Ongoing research on chronic inﬂammation
Like all cellular components of the body, the immune system
undergoes age-associated remodeling. Considered a hallmark of
aging, these changes are characterized by alterations in T-cell
subtypes and T-cell function (‘immunosenescence’) and increased
levels of inﬂammatory cytokines and markers of immune
activation (‘inﬂammaging’) (Lopez-Otin et al., 2013). These
changes manifest as poor response to vaccination, increased
susceptibility to infection, and higher risk of cancer, CVD, and
death in the elderly. These changes that occur in the immune
system with normal aging show similarities with processes that
occur in HIV infection (Deeks, 2011).
The increased levels of inﬂammation prior to ART contribute to
immune suppression and mortality among HIV-positive individu-
als (Kalayjian et al., 2010; Ledwaba et al., 2012). ART effectively
suppresses HIV to undetectable levels in the blood but fails to
eradicate infection. Studies have shown that despite suppressive
ART, the level of HIV-associated inﬂammation decreases but
remains elevated compared to individuals without HIV. The
contribution of this residual inﬂammation among patients
receiving fully suppressive ART to the development of non-
AIDS-deﬁning illnesses and mortality remains unclear. Some
studies have shown that among individuals with fully suppressed
HIV, markers of inﬂammation, coagulation, and gut microbial
translocation remain signiﬁcantly associated with all-cause
mortality after adjusting for traditional risk factors (Tien et al.,
2010; Tenorio et al., 2014; Hunt et al., 2014). Another study
demonstrated that markers of TNF-a activation were signiﬁcantly
associated with incident type 2 diabetes (Brown et al., 2010).
However, these studies are limited because of residual confound-
ing. For example, important variables such as family history of
premature CVD, smoking, composite Framingham risk, and more
importantly, socioeconomic status, are not always included in the
regression models used in these studies. The latter, like age, is a
powerful predictor of morbidity and mortality (Stringhini et al.,
2017; Tobias, 2017). However, large databases of HIV-positive
individuals used for research often fail to or under-represent this
important variable.
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Whether decreasing residual inﬂammation further after the
achievement of full virological suppression and/or robust immu-
nological recovery (CD4+ T-cell count >500 cell/ml) with ART will
lead to a further reduction in mortality and morbidity among
PLWH remains unknown. Statins have emerged as the leading
candidate drugs in potentially curbing the effects of inﬂammation.
Studies in the general population have shown that statin therapy
decreases chronic inﬂammation and reduces all-cause mortality by
14% (Taylor et al., 2013). In PLWH, statins have been shown to
modestly reduce chronic inﬂammation and immune activation
among individuals who are treatment-naïve (Ganesan et al., 2011).
Among individuals receiving stable ART, the data are mixed. Data
from Stopping Atherosclerosis and Treating Unhealthy Bone with
Rosuvastatin in HIV (SATURN-HIV) showed a signiﬁcant reduction
in inﬂammation after 48 weeks of rosuvastatin in individuals
receiving ART (Funderburg et al., 2015). However, in that study, 22%
of the participants were not virologically suppressed. In a study
that restricted enrolment to patients with full virological
suppression on stable ART, atorvastatin did not lead to further
reductions in the levels of inﬂammation, although it resulted in
signiﬁcant changes in lipid proﬁle over the study period (Nixon
et al., 2017).
In retrospective studies, statins have been shown to reduce all-
cause mortality, decrease malignancy risk, and lower cirrhosis risk
among HIV/HCV-co-infected patients (Lang et al., 2015; Moore
et al., 2011; Overton et al., 2013; Chao et al., 2011; Galli et al., 2014;
Oliver et al., 2016). It must be noted, however, that other studies
have not shown a mortality beneﬁt with statin use (Overton et al.,
2013; Krsak et al., 2015; Rasmussen et al., 2013). Statin therapy has
also not been shown to reduce bone loss in a randomized trial of
HIV-positive subjects receiving suppressive ART (Erlandson et al.,
2016). Of note, retrospective studies have not shown a beneﬁt of
statin therapy for CVD risk reduction (e.g., myocardial infarction,
stroke) among individuals on stable ART (Overton et al., 2013;
Krsak et al., 2015). However, statin use has been shown in
randomized controlled trials to improve surrogate markers of CVD
among individuals with mostly suppressed viremia (e.g., carotid
intima media thickness, arterial inﬂammation) (Lo et al., 2015;
Longenecker et al., 2016). The Randomized Trial to Prevent
Vascular Events in HIV (REPRIEVE), the ﬁrst randomized controlled
trial designed to determine whether statin therapy would reduce
cardiovascular events among HIV-infected individuals, is currently
ongoing. Results from this multicenter study will provide more
insights into the beneﬁts of statin use in the primary prevention of
CVD among HIV-infected persons.
Future directions
Future studies that aim to understand the pathophysiology and
contribution of the residual inﬂammation among HIV-infected
individuals on fully suppressive ART should be pursued. It remains
unknown whether age-associated inﬂammation will aggravate
residual HIV-associated inﬂammation in these patients over time.
These studies, together with HIV cure research, represent
signiﬁcant challenges in the path towards successful aging. Future
research should also take advantage of the low-hanging fruit in this
path towards successful aging. These include improving the
cascade of HIV care and addressing health disparity, increasing
the proportion of HIV-infected persons who are receiving
suppressive ART and maintained in care, using safer antiretroviral
medications, and improving the uptake of primary care preventa-
tive guidelines among HIV-infected persons including statin
therapy, lifestyle modiﬁcation, smoking cessation, and the
treatment of risk factors.
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